QIAGEN N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets. The company markets products in approximately 100 countries. Products The company leverages its leadership in Sample to Insight molecular technologies across a range of applications and customer classes through approximately 500 core consumable products (sample and assay kits), as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. Its bioinformatics solutions connect laboratory workflows and process extensive amounts of genomic data, reporting relevant insights to enable scientists or clinicians to decide on further action. Its revenue streams can be seen in two main categories: consumables and related revenue, and automation platforms and instruments. Consumables and related revenues The company’s assay technologies are either generic or pre-designed, with each kit, including reagents to enable customers to target molecules of interest for detection on platforms such as PCR or next-generation sequencing (NGS). The company’s sample technologies are used to isolate, purify and stabilize nucleic acids and proteins. Applications include plasmid DNA purification, RNA purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after PCR and sequencing, and library preparation for sequencing. Its assay technologies enable detection of specific or open molecular targets. Applications include open, general purpose PCR reagents or kits for the specific detection of viral or bacterial pathogens and parasites in humans and animals, pharmacogenomic testing and genotyping, as well as a portfolio of gene panels enabling next-generation sequencing to identify genetic mutations relevant to clinical or research targets in diseases, such as cancer. The QIAGEN Knowledge Base is a deep repository of expertly curated biological interactions and functional annotations covering millions of relationships between proteins, genes, complexes, cells, tissues, drugs and diseases. This resource, which is updated continually, provides content and context for a number of the company’s bioinformatics solutions. Ingenuity Variant Analysis provides a cloud-based platform to evaluate data generated by high-throughput NGS technologies. Tapping into the QIAGEN Knowledge Base, it quickly filters genetic variants from testing to identify those most likely to cause disease. QIAGEN Clinical Insight is a evidence-based clinical decision support solution, which was introduced in 2015. This software and content platform, drawing on the QIAGEN Knowledge Base, delivers clinically relevant insights from complex genomic variants identified in NGS. Applications involve tests for somatic and hereditary cancer, leukemia and lymphoma. CLC Genomics Workbench is an analysis package for the analysis and visualization of data from all major NGS platforms. The software incorporates cutting-edge technology and algorithms, supporting key NGS features within genomics, transcriptomics and epigenomics research fields. GeneGlobe, the company’s Web-based portal that enables researchers to search and select from approximately 31 million pre-designed and custom PCR assay kits and NGS assay panels, includes genome-wide solutions for 28 species with any gene or pathway of interest. Related revenues also include royalties, milestone payments from co-development agreements with pharmaceutical companies, payments from technology licenses and patent sales, and custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production on a contract basis. Automation platforms and instruments QIAGEN platforms ar
qiagen n.v. (QGEN:NASDAQ GS)
Venlo, 5912 PL
Phone: 31 77 355 6600
Fax: 31 77 355 6658www.qiagen.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for QGEN.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.